BusinessImmune Design’s GLAAS™ Platform Shown to Modulate the Allergic Immune ResponseBy Nasdaq OMXMar 4, 2016, 1:00 PM UTC
BusinessImmune Design to Report Fourth Quarter and Year End 2015 Financial ResultsBy Nasdaq OMXMar 3, 2016, 1:00 PM UTC
BusinessImmune Design to Present at Cowen and Company 36th Annual Health Care ConferenceBy Nasdaq OMXFeb 29, 2016, 1:00 PM UTC
BusinessImmune Design Announces Positive Topline Data From Three Phase 1 Clinical Trials of Immuno-oncology Product CandidatesBy Nasdaq OMXFeb 9, 2016, 1:00 PM UTC
BusinessImmune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305By Nasdaq OMXJan 8, 2016, 8:42 PM UTC
